Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Novozymes Biopharma AB

BioPhotonics
Apr 2009
Novozymes Biopharma AB of Lund, Sweden, and Upperton Ltd. of Nottingham, UK, have been granted a European patent for their targeted drug delivery technology. The patent describes methods of conjugating antibodies and other targeting agents to protein carriers by using a heterobifunctional linker, making it possible to deliver large quantities of drugs to selected sites in the body.

Biophotonicsheterobifunctional linkerNews & FeaturesNovozymes Biopharma ABUpperton Ltd

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.